Low vision depression prevention trial in age-related macular degeneration: A randomized clinical trial

Barry W. Rovner, Robin J. Casten, Mark T. Hegel, Robert W. Massof, Benjamin E. Leiby, Allen C. Ho, William S. Tasman

Research output: Contribution to journalArticle

Abstract

Purpose To compare the efficacy of behavior activation (BA) + low vision rehabilitation (LVR) with supportive therapy (ST) + LVR to prevent depressive disorders in patients with age-related macular degeneration (AMD).

Design Single-masked, attention-controlled, randomized, clinical trial with outcome assessment at 4 months.

ParticipantsPatients with AMD and subsyndromal depressive symptoms attending retina practices (n = 188). Interventions Before randomization, all subjects had 2 outpatient LVR visits, and were then randomized to in-home BA+LVR or ST+LVR. Behavior activation is a structured behavioral treatment that aims to increase adaptive behaviors and achieve valued goals. Supportive therapy is a nondirective, psychological treatment that provides emotional support and controls for attention.

Main Outcome Measures The Diagnostic and Statistical Manual IV defined depressive disorder based on the Patient Health Questionnaire-9 (primary outcome), Activities Inventory, National Eye Institute Vision Function Questionnaire-25 plus Supplement (NEI-VFQ), and NEI-VFQ quality of life (secondary outcomes).

Results At 4 months, 11 BA+LVR subjects (12.6%) and 18 ST+LVR subjects (23.4%) developed a depressive disorder (relative risk [RR], 0.54; 95% CI, 0.27-1.06; P = 0.067). In planned adjusted analyses the RR was 0.51 (95% CI, 0.27-0.98; P = 0.04). A mediational analysis suggested that BA+LVR prevented depression to the extent that it enabled subjects to remain socially engaged. In addition, BA+LVR was associated with greater improvements in functional vision than ST+LVR, although there was no significant between-group difference. There was no significant change or between-group difference in quality of life.

Conclusions An integrated mental health and low vision intervention halved the incidence of depressive disorders relative to standard outpatient LVR in patients with AMD. As the population ages, the number of persons with AMD and the adverse effects of comorbid depression will increase. Promoting interactions between ophthalmology, optometry, rehabilitation, psychiatry, and behavioral psychology may prevent depression in this population.

Original languageEnglish (US)
Pages (from-to)2204-2211
Number of pages8
JournalOphthalmology
Volume121
Issue number11
DOIs
StatePublished - Nov 1 2014

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Low vision depression prevention trial in age-related macular degeneration: A randomized clinical trial'. Together they form a unique fingerprint.

  • Cite this

    Rovner, B. W., Casten, R. J., Hegel, M. T., Massof, R. W., Leiby, B. E., Ho, A. C., & Tasman, W. S. (2014). Low vision depression prevention trial in age-related macular degeneration: A randomized clinical trial. Ophthalmology, 121(11), 2204-2211. https://doi.org/10.1016/j.ophtha.2014.05.002